Qualigen Therapeutics Inc (QLGN) — Cash Flow-to-Debt Ratio
Qualigen Therapeutics Inc (QLGN) has a Cash Flow-to-Debt Ratio of -0.43x as of September 2025, meaning its operating cash flow of $-2.14 Million could theoretically repay 0% of its total liabilities ($4.92 Million) in one year. Check Qualigen Therapeutics Inc investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Qualigen Therapeutics Inc Cash Flow-to-Debt Ratio (2012–2024)
Historical debt coverage capacity for Qualigen Therapeutics Inc across 13 annual periods. Also explore QLGN asset base for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Qualigen Therapeutics Inc (2012–2024)
Year-by-year debt coverage analysis for Qualigen Therapeutics Inc. For market capitalisation and broader financial context, see Qualigen Therapeutics Inc market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -3.15x | $-6.33 Million | $2.01 Million | ▼ -26.5% |
| 2023 | -2.49x | $-10.30 Million | $4.14 Million | ▼ -94.0% |
| 2022 | -1.28x | $-13.25 Million | $10.32 Million | ▲ +45.3% |
| 2021 | -2.35x | $-14.73 Million | $6.27 Million | ▼ -160.8% |
| 2020 | -0.90x | $-9.76 Million | $10.83 Million | ▼ -2765.8% |
| 2019 | 0.03x | $57.33K | $1.70 Million | ▲ +101.5% |
| 2018 | -2.25x | $-13.33 Million | $5.93 Million | ▲ +17.8% |
| 2017 | -2.73x | $-7.40 Million | $2.71 Million | ▲ +43.7% |
| 2016 | -4.85x | $-15.21 Million | $3.13 Million | ▼ -14.9% |
| 2015 | -4.22x | $-5.72 Million | $1.35 Million | ▼ -357.9% |
| 2014 | -0.92x | $-1.16 Million | $1.25 Million | ▲ +57.7% |
| 2013 | -2.18x | $-1.96 Million | $897.96K | ▲ +35.5% |
| 2012 | -3.38x | $-3.08 Million | $910.48K | — |